Q4 report was disappointing and everything in the short term is...

Q4 report was disappointing and everything in the short term is leveraged on 3M saving the day post there big merger... A lot of deflecting put on the partners in 2019 so I hope for shareholders sake, they change things up in 2020. My doctor friend in the states said the biggest issue with BlastX is the excessive price combined with no reimbursement - so while I am no expert on what all that means per say, it leads me to believe that they have a big problem moving a lot of this product? So how does 3M work around that? This quarter will be critical to determining if NXS moving in the right direction or continuing to play the blame game with there partners. Sales in 2019 were extremely disappointing and expenses extremely high so something has to change. The technology is undeniable but the sales strategy may be broken? Looking for more clarity at the end of this quarter.